

PATENT Customer No. 22,852 Attorney Docket No. 05552.1464-00

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

in re Application of:	)
Udo KRUPKA	) Group Art Unit: To be assigned
Application No.: 10/561,343	) Examiner: To be assigned
Filed: December 20, 2005	)
For: NOVEL SUIRFACE PROTEIN (HBsAg) VARIANT OF THE HEPATITIS B VIRUS	) Confirmation No.: 5930

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

## SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicant brings to the attention of the Office the documents listed on the attached PTO/SB/08 Form. Copies of the listed documents are enclosed. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

Applicant respectfully requests that the Office consider the listed documents and indicate that they were considered by making appropriate notations on the attached PTO/SB/08 Form.

Application No.: 10/561,343 Attorney Docket No. 05552.1464-00

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Office applies any of the documents as prior art against any claim in the application and Applicant determines that the cited documents do not constitute "prior art" under United States law, Applicant reserves the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted.

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.

Dated: June 23, 2006

Elizabeth A. Dohert

Reg. No. 50,894

Form PTO/SB/	08: Substitute for f	om 1449A/PTO		C	omplete if Known	OIPE	_
				Application Number	10/561,343	/ %	7
INFO	RMATION	DISCLOS	URE	Filing Date	December 20, 2005	/	֓֡֡֡֓֞֡֡֡֡֡֡֡֡֡֡֡֡֡֡֡֡֡֡֡֡֡֡֡֡֡֡
STAT	EMENT B	Y APPLIC	ANT	First Named Inventor	Udo KRUPKA	JUN 2 3 7006	-
				Art Unit	To be assigned	10	۳
	Use as many shee	ts as necessary)		Examiner Name	To be assigned	13	ラ
Sheet	11	of	1	Attorney Docket Number	05552.1464-00	The same	<u>_</u>

Examiner Initials	Cite	Cite No. 1 Number-Kind Code <sup>2</sup> (if known)	Issue or Name of Patentee or Publication Date MM-DD-YYYY	Name of Patentee or	Pages, Columns, Lines, Where	
	No. Nt			Applicant of Cited Document	Relevant Passages or Relevant Figures Appear	
		US-				
		US-				
		US-				
		US-				
		US-				

Note: Copies of the U.S. Patent Documents are not Required in IDS filed after October 21, 2004

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document  Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> ( <i>it known</i> )	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation

	NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Initials No. (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		Translation <sup>6</sup>	
		R. SCOPES, <i>Protein Purification: Principles and Practice</i> (3 <sup>rd</sup> edition), Springer Verlag (1994), table of contents only.		
		E. HARLOW et al., Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press (1988), table of contents only.		

Evaminas			
Examiner		Date	
Signature			
Olgitature	<u></u>	Considered	i

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.